In vitro effect of STI571 on expression of c-kit in bone marrow cells from patients with acute non-lymphocytic leukemia.
- Author:
Lin-Fang Tan TAI
1
;
Zheng-Shan YI
;
Ru FENG
Author Information
1. Department of Hematology, Nanfang Hospital, The First Military Medical University, Guangzhou, 510515 China.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Aged;
Antineoplastic Agents;
pharmacology;
Benzamides;
Bone Marrow Cells;
drug effects;
metabolism;
Female;
Gene Expression Regulation, Neoplastic;
drug effects;
Humans;
Imatinib Mesylate;
Leukemia, Myeloid, Acute;
blood;
genetics;
pathology;
Male;
Middle Aged;
Piperazines;
pharmacology;
Proto-Oncogene Proteins c-kit;
genetics;
Pyrimidines;
pharmacology;
RNA, Messenger;
drug effects;
genetics;
metabolism;
Reverse Transcriptase Polymerase Chain Reaction
- From:
Journal of Experimental Hematology
2003;11(3):256-258
- CountryChina
- Language:Chinese
-
Abstract:
This study was designed to explore the influence of STI571, a tyrosine kinase inhibitor, on the expression of c-kit in the bone marrow cells from patients with acute non-lymphocytic leukemia (ANLL). The cells were exposed to various concentration of STI571 for 72 hours, the expression of c-kit mRNA and CD117 was assayed by RT-PCR and flow cytometry, respectively. The results showed that STI571 treatment induced concentration-dependent decrease of c-kit and CD117 expression, which was significant lower than that in group before treatment and untreated control groups (P < 0.05) and 0.1 micro mol/L STI571 group was significantly higher than that in 10 micro mol/L group (P < 0.05). It is concluded that STI571 has an obvious effect on the restraint of c-kit in ANLL cells.
